MarketCap
Facebook
X
Telegram
Nabriva Therapeutics plc Income Statement 2022-2011 | NBRV
Brief overview of financial results at Nabriva Therapeutics plc
The comparison covers a five-year financial horizon. According to figures from Nabriva Therapeutics plc, revenue changed from 5.3 million dollars to 36.9 million dollars over five years. Across the full period, sales moved by +594.4%; the average annual rate was 47.3%. Revenue growth reflects a pronounced phase of business expansion.
The five-year EBITDA result moved by +24.6%: from −73.3 million dollars to −55.3 million dollars. The operating result developed less favorably than sales. The EBITDA share of revenue changed from −1378.8% to −149.6%. The business generated more EBITDA from each unit of revenue.
Comparing the endpoints shows a move from −$74.4 million to −$57.2 million. The negative result improved without reaching break-even.
The market value of the business moved from 1.5 billion dollars to 4.1 million dollars, or −99.7%. Financial performance is stronger than the share-price trend.
What the figures show
The financial profile remains mixed, with strengths and risks moving in different directions. The strongest signals are sales growth, net-income growth and higher operating efficiency. The main areas of concern are a weaker market valuation and limited operating profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Nabriva Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.1 M | 787 K | 1.23 M | 100 M | 101 M | 1.53 B | 232 M | 95.4 M | - | - | - | - |
Shares |
2.68 M | 1.73 M | 514 K | 7.42 M | 5.08 M | 29.8 M | 2.15 M | 1.06 M | 325 K | - | - | - |
Historical Prices |
1.53 | 0.454 | 2.39 | 13.5 | 19.8 | 51.4 | 108 | 90.1 | - | - | - | - |
Net Income |
-57.2 M | -49.4 M | -69.5 M | -82.8 M | -115 M | -74.4 M | -54.9 M | -47 M | -14.2 M | 15.5 M | - | - |
Revenue |
36.9 M | 28.9 M | 5.03 M | 9.48 M | 9.66 M | 5.32 M | 6.48 M | - | - | - | - | - |
Cost of Revenue |
28.6 M | 13.1 M | 766 K | 70 K | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 7.68 M | - | - | - | - | - | - | - | - |
Operating Income |
-55.5 M | -48.5 M | -66.1 M | -79.5 M | -114 M | -73.8 M | -55 M | -27.8 M | -10.7 M | - | - | - |
Interest Expense |
698 K | 901 K | 1.65 M | 3.39 M | 133 K | 43 K | 75 K | 22.1 M | 2.91 M | - | - | - |
EBITDA |
-55.3 M | -48.2 M | -65.7 M | -79.1 M | -114 M | -73.3 M | -54.8 M | -27.6 M | -10.5 M | 28.1 M | - | - |
Operating Expenses |
- | - | - | 87.2 M | 31.7 M | 23.4 M | 61.5 M | 31.5 M | 13.1 M | - | - | - |
General and Administrative Expenses |
45.3 M | 51.6 M | 55.3 M | 62.5 M | 41.7 M | 29.5 M | 13.5 M | 7.92 M | 3.74 M | 3.91 M | - | - |
All numbers in USD currency
Quarterly Income Statement Nabriva Therapeutics plc
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
3.23 M | 3.2 M | 3.2 M | 2.73 M | 63.2 M | 58.8 M | 2.27 M | 50.5 M | 40.6 M | 26.4 M | 21.1 M | 145 M | 113 M | 94.6 M | 9.45 M | 75.2 M | 72.5 M | 68.7 M | 67 M | 58.4 M | 40.5 M | 36.9 M | 36.7 M | 28.1 M | 27.2 M | 2.72 M | 2.72 M | 21.3 M | 21.3 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-12.1 M | -8.7 M | - | -11.5 M | -11.1 M | -11.8 M | - | -10.7 M | -11.8 M | -14 M | - | -13 M | -15.4 M | -23.3 M | -23 M | -17.8 M | -21.7 M | -20.2 M | -30.8 M | -52.8 M | -17.8 M | -13.3 M | -22.3 M | -22.3 M | -14.6 M | -15.2 M | -15.2 M | -14 M | -12.1 M | -13.6 M | -7.96 M | -8.42 M | -24.5 M | -6.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
2.24 M | 7.59 M | - | 9.15 M | 9.19 M | 8.02 M | - | 8.86 M | 8.24 M | 2.53 M | - | 1.29 M | 487 K | 789 K | 333 K | 6.92 M | 525 K | 1.7 M | 797 K | 461 K | 847 K | 7.55 M | 1.12 M | 1.47 M | 1.05 M | 1.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
9.07 M | 4.44 M | - | 4.42 M | 4.46 M | 3.36 M | - | 4.2 M | 3.62 M | 62 K | - | 25 K | 368 K | 8 K | - | 15 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-12 M | -8.48 M | - | -11.2 M | -10.4 M | -11.6 M | - | -10.8 M | -11.4 M | -13.4 M | - | -13.2 M | -14.5 M | -20.2 M | -22.1 M | -17.2 M | -21 M | -19.2 M | -30.9 M | -52.9 M | -17.7 M | -12.9 M | -22.3 M | -20.7 M | -15.6 M | -15.2 M | -14.7 M | -14.1 M | -11.5 M | -14.7 M | -10.2 M | -8.33 M | -5.52 M | -3.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-39 K | -31 K | - | 354 K | -92 K | 308 K | - | 221 K | 241 K | 222 K | - | 261 K | 251 K | 1.02 M | - | 709 K | 904 K | 899 K | - | 8 K | 7 K | 4 K | - | 42 K | 3 K | 1 K | - | 35 K | - | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-12 M | -8.45 M | - | -11 M | -10.2 M | -11.5 M | - | -10.5 M | -11.2 M | -13.3 M | - | -12.9 M | -14.2 M | -20.1 M | -22.1 M | -17 M | -20.7 M | -19.1 M | -30.9 M | -52.5 M | -17.4 M | -12.7 M | -22.3 M | -20.4 M | -15.4 M | -15.1 M | -14.7 M | -13.9 M | -11.4 M | -14.7 M | -10.2 M | -8.33 M | -5.52 M | -3.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.5 M | 20.9 M | 31.7 M | 53.4 M | 18.6 M | 20.4 M | 23.4 M | 22.2 M | 16.6 M | 16.9 M | 17 M | 15 M | 13.3 M | 16.1 M | 11.2 M | 9.62 M | 6.42 M | 4.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.11 M | 9 M | - | 11.9 M | 11 M | 12.7 M | - | 12.3 M | 12.9 M | 12 M | - | 11 M | 8.07 M | 16 M | - | 18.5 M | 13.4 M | 13.4 M | - | 12.6 M | 8.84 M | 10.1 M | - | 9.52 M | 5.57 M | 4.22 M | - | 2.99 M | 3.37 M | 3.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Nabriva Therapeutics plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
China
France
Singapore
Britain
Germany
Israel
Russia
Belgium
